News

The deal will take the Nasdaq-listed Lantheus private. Under the agreement, Curium US will purchase all outstanding shares of Lantheus for $102.50 per share upon closing. Lantheus’ shareholders

The agreement covers the use of senaparib as a maintenance monotherapy for adult patients with advanced epithelial high-grade ovarian, fallopian tube, and primary peritoneal cancer. Under the agreement,

The company said existing investors Duquesne Family Office and Bristol Myers Squibb participated in the round, joined by new investors Catalio Capital Management, Eli Lilly and Company, and

The partnership is intended to jointly advance methods that address one of the main challenges for RNA medicines: delivering treatments to additional tissue types. While existing RNA therapies

The investment will support the expansion of Resilience’s advanced manufacturing operations in the Cincinnati region and create at least 400 new jobs. With this initiative, the total number

Repatha is intended for adults with established or high risk of atherosclerotic cardiovascular disease (ASCVD) and aims to reduce the risk by decreasing low-density lipoprotein cholesterol (LDL-C) levels,

The companies will become 100%-owned subsidiaries of Caldera Therapeutics, a newly formed holding company. This combined company intends to apply for a listing on the Nasdaq Capital Market

Targeting long non-coding ribonucleic acid (lncRNA), HTX-001 is being evaluated in a Phase Ia/b clinical trial. The first cohort in this trial was dosed in May. This antisense

The deal grants CORE Biomedicine rights to develop and commercialise a portfolio of cancer therapies originally discovered by Eisai and its affiliates. The licensed assets focus on targeting